2023 annual financial data

Lyell Immunopharma 2023 Financial results

Direct answer

Revenue was 130,000 USD.

Operating income was -247,008,000 USD and net income was -234,632,000 USD.
Operating cash flow was -163,694,000 USD.

Get free Lyell Immunopharma email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
130,000 USD
Operating income
-247,008,000 USD
Net income
-234,632,000 USD
Operating cash flow
-163,694,000 USD